Deferasirox是医保药物吗？

It is a new type of oral iron-removing agent, mainly used in 2-year-old patients with chronic iron overload caused by blood transfusion. Clinical research is currently underway in China.

Deferasirox is used to treat chronic iron overload caused by frequent blood transfusions in beta-thalassemia patients older than 6 years old, and has the advantage of good treatment compliance. Deferasirox is an oral active chelator that is highly selective for iron.

Deferasirox is currently on the market in China. So, is Deferasirox a medical insurance drug?

It is understood that Deferasirox has not yet officially entered the medical insurance, it is not a medical insurance drug, and the patient needs to pay for it at his own expense!

The price of Deferasirox after it was launched in China was relatively high, with a box costing about $2,000. For an ordinary person weighing 60kg, the cost of taking Deferasirox for a month is more than about $24,000. It can be seen that it is difficult for ordinary families to accept this price and cannot afford it!

The foreign version of Deferasirox is more friendly to the people. Novartis of Switzerland imported Deferasirox to India. The specification is 400mg*30 tablets/box and the price is about $700.  

The specification of Deferasirox produced by Indian pharmaceutical factory is 500*30 tablets/box, and the price is about 500$. Due to the floating exchange rate, the price will be different. Please consult Medical Travel for specific details!

, is an iron chelator product developed by the Swiss pharmaceutical company Novartis. It is the first oral iron-removing agent approved by the US FDA for routine use. Studies have shown that it has good safety and tolerability, can significantly reduce the iron load on the heart and liver, and is easily accepted by patients. At the same time, it also has pharmacological properties such as antifungal, anticell proliferation, antimalarial, antioxidative stress damage, and anticytotoxic-induced apoptosis; it can be used for the treatment of secondary hemochromatosis, porphyria cutanea tarda and other diseases.